Evidence map›Paper›PMID 41029278›Full record

ArticleBMC cancer2025

Early treatment-related morbidity and mortality of children with non-Hodgkin's lymphoma treated at Tikur Anbesa Specialized Hospital with modified ALCL protocol: prospective cohort study.

Mulualeme Nigusie, Haileyesus Adam, Sheila Weitzman, Abraham Kassahun, Abdulkadir Gidey, Daniel Hailu, Gashaw Arega, Getasew Fikad, Tigist Chalachew, Julie Broas and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mulualeme NigusieHawassa University, Hawassa, Ethiopia.
Haileyesus AdamAddis Abeba University, Addis Abeba, Ethiopia.
Sheila WeitzmanSick Kid Hospital, Toronto, Canada.
Abraham KassahunHawassa University Comprehensive Specialized Hospital, Hawassa, Ethiopia. Abrishk46@gmail.com.
Abdulkadir GideyAddis Ababa University, Addis Abeba, Ethiopia.
Daniel HailuAddis Ababa University, Addis Abeba, Ethiopia.
Gashaw AregaAddis Ababa University, Addis Abeba, Ethiopia.
Getasew FikadBahir Dar University, Bahir Dar, Ethiopia.
Tigist ChalachewAddis Ababa University, Addis Abeba, Ethiopia.
Julie Broas, Washington, DC, USA.
Aziza ShadHerman and Walter Samuleson Children's Hospital at Sinai, Baltimore, MD, USA.
Abel HailuAddis Ababa University, Addis Abeba, Ethiopia.
Yonas Alemayehu ZewdeHawassa University, Hawassa, Ethiopia.
Menberu Moges AyeleWachemo University, Hosana, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChildhood non-Hodgkin lymphoma is a varied collection of malignant neoplasms that includes all lymphomas that are not categorized as Hodgkin lymphoma. It is the third most prevalent malignancy after leukemia and brain tumors. Over the last twenty years, significant improvements in chemotherapy combination, intensification, and supportive care have led to significant survival in high-income countries. However, in low- and middle-income countries, underlying malnutrition, delayed and advanced presentation, inadequate supportive care, and infection lead to poor overall outcomes and treatment-related early or late mortality; this study aimed to Assess, early induction phase treatment-related mortality and associated factors of children with non-Hodgkin's Lymphoma treated at Tikur Anbesa Specialized Hospital (TASH) treated with modified ALCL protocol.

methodsA hospital-based Prospective cohort study design was conducted on a total of 50 children with confirmed non-Hodgkin's lymphoma treated at TASH from March 2023 to June 2024. data were collected using a structured questionnaire and entered into Epi Data 3.1 then exported to SPSS for analysis. The categorical variables in the study were presented using frequency, and percentage, and compared between groups using the chi-square test. Multivariate logistic regression analysis, cox proportional hazard ratio, and Kaplan Meier analysis were performed to analyze the survival and factors associated with early treatment-related mortality.

resultsThe mean age at diagnosis was 5 years; abdominal swelling and constitutional symptoms like fever and weight loss were the common presenting complaints. Burkitt lymphoma accounts for 40% of the diagnosis and the majority of the patients present with advanced stage of the disease with elevated LDH (86%), and stage III/IV disease (92%). The majority of the patients had one or more oncologic emergencies at presentation the commonest being tumor lysis syndrome (TLS) (56%) and infection (32%). Infectious complications, hematologic toxicity, mucositis, and typhlitis were the commonly encountered chemotherapy-related toxicities and 24% of patients died during the induction phase.

conclusionThe induction phase of treatment resulted in a significantly high death rate (24%) for children and adolescents with NHL who were treated by the locally modified ALCL protocol.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large-Cell, AnaplasticLymphoma, Non-HodgkinAdolescentChildChild, PreschoolFemaleHospitals, SpecialHumansInfantMaleMorbidityProspective Studies

Identifiers

PMID41029278
PMCPMC12482131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.